Grail, Inc. · NASDAQ:GRAL
Grail — American Society of Clinical Oncology (ASCO) 2026
20 slides from Grail's conference presentation, Jun 1, 2026
Slide 1: GRAIL Analyst Call, American Society of Clinical Oncology
GRAIL Analyst Call American Society of Clinical Oncology May 31, 2026 1
Slide 2: Legal Disclosures
CONFIDENTIAL & PROPRIETARY 2 Legal Disclosures This presentation contains forward-looking statements. In some cases, you can identify these statements by forward-looking words such as “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potent
Slide 3: GRAIL at ASCO 2026
3 GRAIL at ASCO 2026 NHS-Galleri Trial PATHFINDER 2 First randomized controlled study of an MCED test Evaluated annual screening with the Galleri test in addition to standard of care screening over three years in more than 142,000 participants Largest interventional MCED study in North America Evalu
Slide 4: NHS-Galleri
GRA:L NHS-Galleri
Slide 5: NHS-Galleri: The First and Only Randomised Controlled Clinical Utility Trial of an MCED Test
CONTROL GROUP Standard of care Three annual screening rounds with additional follow-up to assess long-term impact on cancer outcomes 5 NHS-Galleri: The First and Only Randomised Controlled Clinical Utility Trial of an MCED Test Study Population 142,826 consented participants INTERVENTION GROUP Stand
Slide 6: The NHS-Galleri Trial Assessed Multiple Endpoints
Endpoint Finding Primary | Reduction in combined Stage III and Stage IV cancers 12 deadly cancers Combined reduction not significant Secondary | Reduction in Stage IV cancers 12 deadly cancers >20% reduction in incident rounds Secondary | Increase in Stage I and Stage II cancers 12 deadly cancers ~1
Slide 7: Primary Endpoint: Here is What We Observed
-20% -10% 0% 10% 20% 30% All 3 rounds First round Second round Third round + follow up Stage III Stage IV 7 Primary Endpoint: Here is What We Observed Denominator is control arm; measured on the 12 pre-specified types were lung, head & neck, colorectal, pancreas, myeloma/plasma cell neoplasm, liver/
Slide 8: The Intervention Arm Showed A Clinically Meaningful Stage IV Reduction
The Intervention Arm Showed A Clinically Meaningful Stage IV Reduction: ≥22.0% Reduction in Incident Rounds Denominator is control arm; measured on the 12 pre-specified types were lung, head & neck, colorectal, pancreas, myeloma/plasma cell neoplasm, liver/bile duct, stomach, esophagus, anus, lympho
Slide 9: Detecting Cancers Prior to Stage IV Has Real Benefits For Many Cancers
9 Detecting Cancers Prior to Stage IV Has Real Benefits For Many Cancers 12 prespecified cancer types were lung, head & neck, colorectal, pancreas, myeloma/plasma cell neoplasm, liver/bile duct, stomach, esophagus, anus, lymphoma, ovary, and bladder. Anus and myeloma/plasma cell neoplasms were exclu
Slide 10: 16% More Stage I-II Cancers Were Identified in the Intervention Arm
163 157 57 50 36 23 22 13 11 9 9 9 210 151 49 48 47 28 30 25 24 11 6 18 0 50 100 150 200 Colorectal Lung Head & neck Bladder Lymphoma Pancreas Liver/bile duct Oesophagus Myeloma/ plasma cell neoplasm Stom ach Anus Ovary Control Intervention 10 16% More Stage I-II Cancers Were Identified in the Inter
Slide 11: MCED Test Performance
Cancer Status Cancer diagnosis (n=3,051) No cancer diagnosis (n=194,095) Total (N=197,146) Performance metric (95% CI) MCED Test Result Positive 937 864 1,801 PPVb 52.0% (49.7-54.3%) Negative 2,114 193,231 195,345 NPV 98.92% (98.87-98.96%) Performance metric (95% CI) Episode sensitivityc 30.7% (29.1
Slide 12: Trial Demonstrated Low False Positive Rate & No Related Serious Adverse Events
12 Trial Demonstrated Low False Positive Rate & No Related Serious Adverse Events 864 false positives (303 in first screening round) 54/303 (17.8%) were subsequently diagnosed with cancer in the second or third screening round Of these, 44/54 (81%) had a correct CSO prediction in the first screening
Slide 13: Adding Galleri to Standard of Care Quadrupled the Number of Screening-Detected Cancers
13 Adding Galleri to Standard of Care Quadrupled the Number of Screening-Detected Cancers MCED, multi-cancer early detection. aBreast, colorectal, cervical, and lung (for high-risk individuals) cancer. bIncludes 10 unstageable cancers (no staging system exists) and 55 cancers with missing stage info
Slide 14: Galleri Detected Many Deadly Cancers at Early Stages
14 Galleri Detected Many Deadly Cancers at Early Stages MCED, multi-cancer early detection. Total Galleri cancers detected are 937; table excludes cancer types with 10 or fewer detected cancers: Bladder, Anus, Melanoma, CUP, Mesothelioma, Small Intestine, Germ Cell, Vulva, Brain, Penis, Vagina, Mult
Slide 15: PATHFINDER-2
PATHFINDER-2 15
Slide 16: PATHFINDER 2: The Largest Interventional MCED Study In North America
16 PATHFINDER 2: The Largest Interventional MCED study In North America Primary Objective: Evaluate safety and performance of the MCED test in a large, diverse intended use population 35,878 Participants Age ≥50 Years from 32 North American healthcare systems with 3 years of follow-up CANCER SIGNAL
Slide 17: Full PATHFINDER-2 Results Were Strong & Consistent With the First 25k
Full PATHFINDER-2 Results Were Strong & Consistent With the First 25k 17 Performance metrics Cancer detection rate Safety ~60% PPV ~0.4% False Positive Rate >90% CSO accuracy >70% Episode sensitivity for 12 deadly cancers 6.5x cancers detected When added to USPSTF A/B screenings(1) 3x cancers detect
Slide 18: Summary
Summary 18
Slide 19: Strong and Consistent Performance Across ~180,000 Participants
Strong and Consistent Performance Across ~180,000 Participants in NHS-Galleri & PATHFINDER 2 First demonstration of stage shift after 3 years of MCED screening • >20% reduction in stage IV cancers after the first screening year • Increase in stages I and II cancers • 25% fewer cancers were diagnosed
Slide 20: Q&A
Q&A 20
GRAIL — American Society of Clinical Oncology (ASCO) 2026 on 6ix